109 results about "Triptolide" patented technology

The invention relates to an active oxygen responsive triptolide prodrug immunoregulation hydrogel preparation as well as a preparation method and application thereof. Triptolide is coupled with an active oxygen responsive group to synthesize a triptolide derivative; then, the triptolide derivative is coupled with polypeptide, and a polypeptide-reactive oxygen responsive group-triptolide conjugate is obtained; then dissolving the polypeptide-active oxygen responsive group-triptolide conjugate in a solvent, standing, and carrying out self-assembly to obtain a triptolide prodrug nanofiber solution; finally, an immunomodulator is added into the triptolide prodrug nanofiber solution for incubation, and the active oxygen responsive triptolide prodrug immunoregulation hydrogel preparation is obtained. The hydrogel preparation disclosed by the invention can responsively release the medicine triptolide and the immunomodulator at the focus part of rheumatoid arthritis, so that the medicine accumulation of non-target organs is reduced, the safety and effectiveness of treatment are improved, and the progress of diseases is effectively controlled.

The invention belongs to the technical field of biological medicine and molecular biology, and particularly relates to ITGB1-siRNA lipid nanoparticles and application of the ITGB1-siRNA lipid nanoparticles in anti-angiogenesis treatment. Specifically, the ITGB1-siRNA lipid nanoparticles are successfully prepared, the lipid nanoparticles are loaded with integrin beta1 small interfering RNA (ITGB1-siRNA), are modified with triptolide (TP) and are coupled with anti-Flt1 peptide, so that the lipid nanoparticles can target vascular endothelial cells (VEC) and pericytes of CNV, and a good treatment effect on the CNV is achieved. Therefore, the lipid nanoparticles researched and developed by the invention are expected to become a new choice for treating the CNV-related eye diseases, and have good practical application value.

The invention provides a traditional Chinese medicine composition for treating dry eyes as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine compositions. The preparation method of the traditional Chinese medicine composition comprises the following steps: taking 3-12 parts by weight of tripterygium wilfordii and 3-12 parts by weight of mint as raw material medicines, mixing, adding water, decocting, carrying out solid-liquid separation, and concentrating the filtrate to obtain the traditional Chinese medicine composition. According to the invention, tripterygium wilfordii is taken as a main medicine and is matched with mint with the effect of dispelling wind and heat to jointly form the eye fumigating prescription capable of dispelling wind and clearing heat, and the eye fumigating prescription comprises active ingredients such as triptolide, tripterine and the like, and can regulate and control inflammatory response of ocular surface; local administration is carried out by adopting an ultrasonic atomization method, so that liver and kidney injury caused by liver and kidney metabolism of oral medicines can be avoided, most of active ingredients only play roles in eyes and do not enter blood circulation, the toxicity of tripterygium wilfordii is reduced, only anti-inflammatory and immunosuppression efficacy of tripterygium wilfordii is taken, local administration directly reaches a disease site, and the treatment effect on dry eyes is definite.

The invention discloses a method for researching the influence of triptolide on the proliferation of multiple myeloma cells by regulating miR-381 / HMGB1 (High Mobility Group Box 1), and relates to the technical field of biology. Research results of the research method show that miR-381 methylation silencing in RPMI8226 cells is an important reason for promoting cell proliferation, TPL inhibits proliferation of the RPMI8226 cells by reversing a miR-381 methylation modification state, inducing and restoring expression and regulating HMGB1 genes in a targeted manner, and the research lays a theoretical basis for exploring an anti-MM action mechanism of TPL.

The invention belongs to the field of genetic engineering and synthetic biology, and provides a novel cytochrome P450 enzyme derived from cephalotaxus plants, a nucleotide, a carrier and a host of the cytochrome P450 enzyme, and application of the cytochrome P450 enzyme in preparation of cephalotaxane diterpenoid compounds. The cytochrome P450 enzyme provided by the invention has multiple catalytic functions, can efficiently catalyze oxidation of C-5 site and C-19 site of cephalotaxene, lays a solid foundation for analysis of a cephalotaxane diterpene biosynthetic pathway, and provides a new method for obtaining important active molecules such as cephalotaxus hainanensis lactone and the like by adopting a synthetic biological means.

The curcumin disclosed by the invention has the medicinal activity of preventing and treating mouse spermatogonial cell GC1 injury caused by triptolide, so that the curcumin has potential application value in the aspect of preparing medicines for preventing and treating spermatogonial cell injury caused by a tripterygium wilfordii preparation. Experimental results show that curcumin can be used for protecting spermatogonial cell damage caused by triptolide by regulating oxidative stress and reducing cell apoptosis. Therefore, a new thought and approach can be provided for clinical application of traditional Chinese medicine in male reproductive system injury repair. Furthermore, a new thought and a new approach are provided for clinical adjuvant medication of the triptolide, namely, the tripterygium wilfordii preparation containing the triptolide and the curcumin is developed, so that the anti-cancer drug activity and the like of the triptolide can be exerted, the reproductive injury side effect of the triptolide is inhibited or relieved through the curcumin, and the application prospect is wide. Spermatogonial cell injury induced by triptolide is effectively recovered, and particularly, spermatogonial cell oxidative stress injury and apoptosis caused by triptolide are effectively protected.

The invention relates to the technical field of medicines, in particular to application of triptolide in preparation of a medicine for preventing or treating Alport syndrome. On the basis of a double evidence chain of clinical data and mechanism research, triptolide can be used for preventing and treating the Alport syndrome, an innovative solution is provided for clinical prevention and treatment of the Alport syndrome, and the application prospect is wide.

The invention discloses a production process of a tumor swelling and pain relieving cataplasm patch, and belongs to the technical field of traditional Chinese medicine preparations. According to the process, rheum officinale, golden cypress, turmeric and tripterygium wilfordii stir-fried with vinegar are taken as monarch drugs and are matched with sculellaria barbata and oldenlandia diffusa to enhance the antitumor activity, pseudo-ginseng synergistically improves the transdermal efficiency, and the preparation is optimized through a segmented extraction and nano-targeting technology: 1) adopting supercritical COextraction to extract angelica dahurica and cinnamon volatile oil (20-25MPa and 40-50 DEG C), and carrying out beta-cyclodextrin inclusion; the preparation method comprises the following steps of (1) performing dynamic countercurrent extraction on non-volatile components (70% ethanol at a flow rate of 2.0 mL / min) of other medicinal materials, and coating triptolide (with a particle size of 80-150 nm) in combination with PLGA nanoparticles, and (3) mixing the extract and a composite matrix (sodium polyacrylate-sodium carboxymethyl cellulose-azone), and coating a pH response type chitosan-sodium alginate sustained release layer with the mixture to form the breathable patch.

The present application relates to a kind of cytochrome P450 oxidase CYP716C52 protein, and the CYP716C52 protein coding gene, the protein can catalyze hydroxylation of maytenic acid C2 position to generate triptolide acid C, in turn participate in triptolide biosynthesis.

The invention belongs to the field of new application of medicines, and particularly relates to application of triptolide in preparation of medicines for treating diabetic vascular obstruction complications. Diabetes vascular obstruction is a common serious complication of diabetes and can cause various tissue injuries such as cardiovascular diseases, nephropathy and retinopathy. Experiments prove that the triptolide can remarkably improve the problems of blood vessel blockage, blood flow slowing, abnormal neovascularization and the like caused in a high-glucose environment, and meanwhile, the expression of blood glucose related indexes (such as Glucose and HbA1c) and inflammatory factors (such as TNF-alpha and IL-1beta) is reduced. In addition, triptolide can also protect pancreas from high glucose damage and improve functions of pancreatic beta cells. According to the invention, the clinical application range of the triptolide is expanded, and a new candidate substance is provided for drug treatment of diabetic vascular complications.

The present disclosure provides triptolide conjugates, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat conditions / diseases, such as those related to cancer, immune modulation, and / or inflammation.

The application discloses a triptolide nano-micelle, a synthesis method and application thereof. The nano-micelle is formed by self-assembly of triptolide, metal ions and a modular functional polymer through metal coordination; and the high molecular polymer is covalently connected by a metal coordination group R1, a hydrophilic polymer main chain R2 and a functional end-capping group R3. The application constructs a micelle system by relying on the coordination of three components without an exogenous carrier, avoids potential biological safety risks accompanied by traditional nano-carriers, reduces the complexity of the synthesis process of the medicament, and significantly improves the storage stability of the preparation after freeze-drying. The obtained micelle has good water solubility, can be quickly reconstituted after freeze-drying without a freeze-drying protective agent, has an ATP response drug release characteristic in a tumor microenvironment, and can be used for antitumor drug delivery.

This invention provides the application of triptolide in the preparation of drugs for treating microglial inflammation-related neuroimmunological disorders. Experiments show that triptolide significantly inhibits the expression, migration, phagocytosis, and morphological activation of microglial inflammatory factors, and exerts an anti-microglial inflammatory effect in animal models. Through DARTS technology combined with siRNA screening, ACOX1 was identified as its key target, and the direct binding between the two was verified by CETSA, SPR, and molecular docking.

The invention provides a tripterine sulfated metabolite and application thereof in preparation of a medicine for resisting rheumatoid arthritis, and belongs to the technical field of biological medicine. The tripterine sulfated metabolite is 10-sulfated tripterine which is formed by connecting a HSO3 <-> to the 10-position carbon of the tripterine. Compared with the tripterine, the 10-sulfonated tripterine has no obvious difference in anti-rheumatoid arthritis pharmacological activity, however, the hepatotoxicity in vivo and the cytotoxicity in vitro of the 10-sulfonated tripterine are obviously reduced. The tripterine sulfated metabolite is efficient and low in toxicity, and a wide application prospect is developed for treatment of rheumatoid arthritis.

The embodiment of the invention discloses a pharmaceutical composition for improving cell therapy regeneration and application thereof. The pharmaceutical composition comprises 5 to 15 ng / mL of a transforming growth factor beta, 0.02 to 0.06 [mu] M of triptolide, 8 to 12 ng / mL of a vascular endothelial growth factor, 0.1 to 1 [mu] g / mL of a grape seed extract, 0.8 to 1.6 mg / mL of a trace element solution, 0.5 to 2% of hyaluronic acid, 0.05 to 0.15 [mu] M of cyclosporin and 15 to 25 mM of an HEPES buffer solution. The pharmaceutical composition provided by the invention can effectively promote proliferation and differentiation of hair follicle-derived mesenchymal stem cells, plays a better role in treating alopecia, has the advantages of small side effect, high safety, lower cost and wide applicable crowd, and has better application prospects in clinic.

The invention belongs to the field of biological medicine, and relates to application of triptolide in preparation of a medicine for preventing and treating calcified aortic valve diseases. The triptolide is found to be capable of promoting expression and maturation of CTSD and activating enzyme activity of the CTSD, meanwhile, biogenesis of lysosome in valvular interstitial cells can be promoted by regulating and controlling AKT / mTOR / TFEB signal axes, lysosome functions are improved, autophagy flux is recovered, and finally the effect of treating the calcified aortic valve disease is achieved. A novel treatment medicine is provided for the calcified aortic valve disease.

The invention belongs to the technical field of medicines, and particularly relates to tripterine-loaded nano-particles as well as a preparation method and application thereof, and the tripterine-loaded nano-particles (Cel-GDNPs) comprise ginger exosome (GDNPs) and tripterine (Cel) encapsulated in the ginger exosome. According to the invention, the Cel is used as a therapeutic drug, and the adopted carrier GDNPs has anti-inflammatory activity, so that when the Cel and the GDNPs are used for treating inflammatory diseases such as colitis and the like, the Cel and the GDNPs can play a multi-component synergistic therapeutic effect, and compared with the single use of the Cel or the GDNPs, the expression of proinflammatory factors (such as TNF-alpha, IL-1beta and IL-6) can be more effectively inhibited, so that the synergistic therapeutic effect is realized; a new strategy is provided for developing a novel natural compound preparation.

The present invention relates to the technical field of pharmaceutics, and in particular to a triptolide lignocerate, a liposome thereof and a preparation method therefor. The chemical structural formula of the triptolide lignocerate is represented by formula (I). The triptolide lignocerate provided by the present invention is obtained by esterification of triptolide C14-OH and lignoceric acid. The anti-tumor effectiveness, safety and the like of the triptolide lignocerate liposome are further improved with respect to the prior art, so that a foundation is laid for providing safer and more effective triptolide-related clinical preparations.

The invention provides a breeding method for improving disease resistance of carassius auratus var pengze myxosporidium. The breeding method comprises the following steps of S1, breeding environment treatment, S2, healthy fry selection and purchase, S3, fry disinfection, S4, fry putting, S5, feeding management, S6, water quality management, S7, disease prevention and detection and S8, emergency treatment. In the fry disinfection link, a biological disinfectant composed of tea saponin, a photosensitive component, carvacrol, artesunate and choline-lactic acid ionic liquid is used for soaking carassius auratus var pengze fry, meanwhile, LED light irradiation is used for assistance, the disinfection components can jointly play a role after penetrating into myxosporidium, growth and reproduction of the myxosporidium are inhibited, and therefore the carassius auratus var pengze fry can be prevented from being damaged by the carassius auratus var pengze. Therefore, the effect of effectively killing myxosporidia is achieved. In the emergency treatment link, an insect-resistant agent composed of a glycan-mercaptosuccinic acid conjugate, antibacterial peptide, artesunate, nano-zinc oxide, triptolide and carvacrol is used, and through the synergistic effect of the components, multi-target efficient killing of myxosporidium is achieved.

A pharmaceutical composition containing triptolide or a derivative thereof, as well as methods of using the composition and methods of manufacturing the composition. The composition can be prepared using thermokinetic compounding and can provide improved properties, such as improved bioavailability. The composition can improve the therapeutic treatment of cancers such as pancreatic cancer, breast cancer, bladder cancer, kidney cancer, ovarian cancer, glioblastoma, or melanoma.

The invention discloses application of triptolide ketone in preparation of a medicine for treating sepsis lung injury, and belongs to the technical field of biological medicine. Aiming at the problems that traditional chemical synthetic drugs may cause a large amount of sequelae and antibiotic abuse, and triptolide may cause liver and kidney injury when treating sepsis, research finds that triptolide can be used for treating sepsis lung injury, and can be used for treating sepsis lung injury. According to the application, the protein expression level of HIF-1alpha in proinflammatory activated macrophages is lowered, so that aerobic glycolysis is inhibited, and the effect of treating sepsis lung injury is achieved. Compared with the triptolide alcohol, the triptolide ketone does not cause liver and kidney injury while playing a role in treating the sepsis lung injury, and the curative effect of the triptolide ketone is equivalent to that of the existing medicine 2ME2 for treating the sepsis lung injury, so that the triptolide ketone has important application potential clinically, and can be used for preparing medicines for treating the sepsis lung injury. And a theoretical basis is provided for clinically developing medicines for treating sepsis lung injury.

This invention belongs to the field of biomedical technology, specifically relating to triptolide liposomes (TP-lipo), their combined use, and their application in the prevention and treatment of tumors. To enhance the efficacy of triptolide in the treatment and prevention of tumors such as pancreatic cancer, cervical cancer, ovarian cancer, and colorectal cancer, and to improve its bioavailability and clinical application while reducing toxicity, this invention uses HSPC, DOPS, and cholesterol as liposome components to encapsulate triptolide monomers, thus preparing TP-lipo. Experiments have shown that TP-lipo exhibits anti-tumor activity: it directly kills tumor cells and reverses the immunosuppressive microenvironment, making it a potential drug for tumor treatment. TP-lipo, when used in combination with PD-1 antibodies, or in combination with radiotherapy, chemotherapy, or surgery, demonstrates a potent and synergistic anti-tumor effect with low toxicity. Therefore, the TP-lipo of this invention provides more clinical strategies for tumor treatment.

The invention belongs to the technical field of medicines, and particularly relates to application of triptolide in preparation of a medicine for preventing and / or treating ILC2-mediated allergic airway inflammatory diseases. The invention provides an application of triptolide in drugs for preventing and / or treating allergic airway inflammation ILC2 activation, eosinophilic granulocyte infiltration, airway hyperresponsiveness and lung tissue injury. In addition, in a mouse allergic airway inflammation model induced by papain and IL-33, the relieving effect of the triptolide on the ILC2-mediated airway inflammation is verified. In addition, the invention provides an important earlier-stage basis for developing a triptolide combined medicine or optimizing an administration mode, improving the bioavailability of the triptolide and reducing the toxic and side effects of the triptolide. By focusing ILC2 and exploring the effect of the traditional Chinese medicine triptolide in relieving allergic airway inflammation, a new treatment strategy is expected to be provided for allergic airway inflammation patients, and the cure rate is increased.

The invention discloses triptolide hydrogel, a preparation method thereof and application of the triptolide hydrogel in preparation of a medicine for treating hepatocellular carcinoma, and belongs to the field of biological medicine. The stable injectable hydrogel drug is prepared by utilizing the self-assembly capability of glycyrrhizic acid saponins and loading triptolide, and while the anti-tumor effect of triptolide is played, the toxic and side effects are reduced by virtue of the targeting and anti-inflammatory effects of glycyrrhizic acid, and accurate treatment of liver cancer is realized.

The present invention provides a PROTAC compound derived from triptolide, a preparation method and an application, relating to the technical field of PROTAC compounds. The structure of the PROTAC compound derived from triptolide is shown in Formula I; in Formula I, X is -(CH2) m - or -CH2CH2(OCH2CH2) n -, m is any integer from 2 to 8, and n is any integer from 1 to 3. Through activity tests, the PROTAC compound derived from triptolide has significant anti-proliferation effects on various cancer cells such as colorectal cancer, lung cancer, breast cancer, etc., and its toxicity has decreased significantly. It is expected to prepare new anti-cancer drugs and has good development prospects. #imgabs0#

The invention belongs to the technical field of biological medicine, and particularly relates to a rheumatism immune disease treatment composition combining traditional Chinese medicine active ingredients and immune regulation and application of the rheumatism immune disease treatment composition, and the rheumatism immune disease treatment composition comprises the following components in parts by weight: 10-50 parts of a traditional Chinese medicine active ingredient compound; 0.01 to 1 part of an immune regulation factor; 50 to 90 parts of pharmaceutic adjuvants; wherein the traditional Chinese medicine active component compound is prepared from the following components: astragaloside, artemisinin, curcumin and triptolide in a weight ratio of (2-5): (1-3): (1-4): (0.5-2); the immunoregulation factor is composed of recombinant human interleukin-10 (rhIL-10), a transforming growth factor-beta1 (TGF-beta1) and a CTLA4-Ig fusion protein according to a weight ratio of (1-3): (0.5-2): (1-4). The active ingredients of the traditional Chinese medicine cover a plurality of links of anti-inflammation, anti-oxidation, immunoregulation and the like, and immunoregulatory factors accurately intervene in immune cell activation and a cell factor network to jointly inhibit abnormal immune response.

The present invention provides a kind of breeding method that improves the disease resistance of Pengze crucian carp myxosporeans, comprising the following steps: S1. breeding environment treatment, S2. purchasing healthy fry, S3. fry disinfection, S4. fry delivery, S5. feeding management, S6. water quality management, S7. disease prevention and detection, S8. emergency treatment. In the fry disinfection link, Pengze crucian carp fry are soaked by using a biological disinfectant composed of tea saponin, photosensitizing component, carvacrol, artesunate, and choline-lactic acid ionic liquid, and supplemented with LED light irradiation. These disinfecting components can work together after penetrating into the inside of the myxosporeans, inhibiting their growth and reproduction, thereby achieving the effect of effectively killing the myxosporeans. In the emergency treatment link, the insecticide composed of polysaccharide-mercaptosuccinic acid conjugate, antimicrobial peptide, artesunate, nano zinc oxide, triptolide, and carvacrol is used, and through the synergistic effect between the components, multi-target efficient killing of myxosporeans is achieved.

The application discloses application of triptolide-loaded ZIF-8 sustained-release material in preparation of a forest and farm harmful animal control agent. The triptolide-loaded ZIF-8 sustained-release material is composed of a ZIF-8 carrier and triptolide loaded on the ZIF-8 carrier. Through loading of triptolide by the ZIF-8, the concentration of free triptolide in the system is effectively reduced, the release rate of triptolide is slowed down, the inhibition of triptolide on soil self-nitrogen fixation bacteria can be relieved, and soil urease activity can be adjusted, and the harmful animal control effect and soil ecological environment safety are considered.

The invention belongs to the technical field of biological medicines, and particularly relates to application of an angiotensin II receptor antagonist in preparation of a medicine for preventing and treating renal tubular injury caused by triptolide. According to the invention, the upstream key target protein of the TPL-induced renal tubule injury is determined to be HSPA1 through experiments for the first time, and the problem that the key target spot of TPL toxicity is not determined in the prior art is solved. Based on a key target spot of TPL toxicity, through molecular screening and parallel pharmacodynamic verification on various sartan drugs such as irbesartan, losartan, olmesartan and valsartan, it is determined that the angiotensin II receptor antagonist has a general protection effect on TPL toxicity. Wherein the protective efficacy of irbesartan as a preferable embodiment is obviously superior to that of losartan of the same kind (the efficiency slope is 2.451 to 1.584).

The application discloses a kind of nanomedicine for treating rheumatoid arthritis, including triptolide, Y6 fluorescent probe and poloxamer, triptolide and Y6 fluorescent probe are polymerized by poloxamer to form triptolide nanomedicine Y6@TPL, the average particle size of the triptolide nanomedicine Y6@TPL is 20~300nm.The application combines triptolide with Y6 fluorescent probe, constructs a new type of nano delivery system, the system not only realizes the accurate control release of drug, but also can be enhanced by photo-thermal response Targeted accumulation of rheumatoid arthritis lesion site, significantly improve the selective killing effect of triptolide on inflammatory synoviocytes, while greatly reducing the toxic side effects on normal joint tissue.The nano system integrates photo-thermal therapy, photo-thermal imaging and targeted drug delivery functions, and provides an integrated solution for the diagnosis and treatment of RA.